Direkt zum Inhalt
Merck

Y0001485

Rivastigmin für die Systemeignung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Rivastigmin -tartrat (Salz), ENA-713, Ethylmethyl-carbamsäure-3-[(1S)-1-(dimethylamino)ethyl]phenylester, N-Ethyl-N-methyl-carbamsäure-3-[(1S)-1-(dimethylamino)ethyl]phenylester -tartrat, S-Rivastigmin -tartrat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C14H22N2O2 · C4H6O6
CAS-Nummer:
Molekulargewicht:
400.42
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

rivastigmine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

InChIKey

GWHQHAUAXRMMOT-RWALOXMOSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Rivastigmine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Rivastigmin ist ein für die orale Einnahme verfügbarer, hirnpentrierender, reversibler Cholinesterase-Hemmer, der die kognitive Funktion bei Patienten mit Alzheimer- und Parkinson-Krankheit verbessert. Rivastigmin hemmt sowohl die Butyrylcholinesterase als auch die Acetylcholinesterase.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Skull and crossbonesEnvironment

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Acute Tox. 2 Oral - Aquatic Chronic 2

Lagerklassenschlüssel

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Cassandra Richardson et al.
International journal of geriatric psychiatry, 28(12), 1312-1317 (2013-04-16)
A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of AChEIs on blood
Zhen-Zhen Yang et al.
International journal of pharmaceutics, 452(1-2), 344-354 (2013-05-18)
Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated with cholinergic neurons degeneration. The blood-brain barrier (BBB) not only provides protection for the brain but also hinders the treatment and diagnosis of this neurological disease, because the drugs must
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.